Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial
F&S Reports · 2026-10 · 7 (5) · 417-424
DOI: 10.1016/j.xfre.2026.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift F&S Reports, 2026-10. Verfasst von Tasuku Harada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Tottori, Japan. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co Ltd.
Abstract (Originalsprache)
Objective
To evaluate the efficacy, safety, and pharmacodynamics of linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with heavy menstrual bleeding (HMB) and pain because of uterine fibroids.
Design
Phase 3, multicenter, placebo-controlled, randomized, double-blind, parallel-group, confirmatory study (NCT05445167). Subjects: Premenopausal Japanese women with HMB and moderate-to-severe pain because of uterine fibroids.
Intervention
Patients were randomized 1:1 to once-daily linzagolix 200 mg (n = 48) or placebo (n = 41) for 12 weeks. Main Outcome Measures: The primary endpoints were the proportion of patients with a total pictorial blood loss assessment chart (PBAC) score
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Tottori, Japan.
- Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Clinical Research Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
- Clinical Projects Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
Förderung
- Kissei Pharmaceutical Co Ltd
Zitieren
APA
Harada, T., Osuga, Y., Takahashi, H., Kawai, A., Shimamura, F., & KLH2302 Investigators (2026). Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial. F&S Reports, 7(5), 417-424. https://doi.org/10.1016/j.xfre.2026.07.003
Vancouver
Harada T, Osuga Y, Takahashi H, Kawai A, Shimamura F, KLH2302 Investigators. Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial. F&S Reports. 2026;7(5):417-424. doi:10.1016/j.xfre.2026.07.003
BibTeX
@article{Harada2026,
author = {Harada, Tasuku and Osuga, Yutaka and Takahashi, Hideomi and Kawai, Asuka and Shimamura, Fumiya and KLH2302 Investigators, KLH2302 Investigators},
title = {Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial},
journal = {F&S Reports},
year = {2026},
volume = {7},
number = {5},
pages = {417--424},
doi = {10.1016/j.xfre.2026.07.003}
}
EUVIMED